london euretina
retina race

Dexamethasone intravitreal implant in thirty patients with diabetic macular edema: thirty-one months of follow-up

Session Details

Session Title: New Drug Treatment and Technology I

Session Date/Time: Friday 18/09/2015 | 11:00-12:30

Paper Time: 12:20

Venue: Thalie.

First Author: : P.Busatto ITALY

Co Author(s): :    G. Beltrame              

Abstract Details

PURPOSE:To evaluate the efficacy and safety of dexamethasone intravitreal implant (Ozurdex, DEX 0.7 mg) in the treatment of patients with diabetic macular edema


Department of Ophthalmology Civil Hospital S. Maria degli Angeli Pordenone Italy


Thirty patients with diabetic macular oedema with central retinal thickness > 300 µ were treated with dexamethazone slow release intra-vitreal implant and followed for 31 months. Mean pre op best-corrected visual acuity was of 20/80 ( from 20/200 to 20/32 Snellen equivalent), and mean central retinal thickness (CRT) was of 536 μm ( from 325 to 990 μm) by optical coherence tomography. Retreatment criteria , if eligible , was no more often than every 6 months


Mean BCVA from baseline at study end was 20/50. The percentage of patients with ≥15-letter improvement in BCVA from baseline at study end was 28.6 %. Mean number of treatments received over 31 months was 4.6, (1 DEX every 8,6 months). Mean average reduction in CRT from baseline was (-228, 5 μm). Phakic eyes developed cataract in 80.9 % of cases. Intaocular pressure increase, when present, was well controlled by topical eye drops . No surgery was necessary.


The DEX implant is a safe and effective device in improving BCVA in diabetic patients with macular edema

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy